company background image
6600

SciClone Pharmaceuticals (Holdings) SEHK:6600 Stock Report

Last Price

HK$6.11

Market Cap

HK$4.1b

7D

-3.0%

1Y

-26.8%

Updated

01 Dec, 2022

Data

Company Financials +
6600 fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance4/6
Financial Health5/6
Dividends3/6

6600 Stock Overview

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.

SciClone Pharmaceuticals (Holdings) Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SciClone Pharmaceuticals (Holdings)
Historical stock prices
Current Share PriceHK$6.11
52 Week HighHK$8.98
52 Week LowHK$5.65
Beta0
1 Month Change-1.77%
3 Month Change-10.67%
1 Year Change-26.83%
3 Year Changen/a
5 Year Changen/a
Change since IPO-67.50%

Recent News & Updates

Recent updates

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Shareholder Returns

6600HK PharmaceuticalsHK Market
7D-3.0%2.9%4.5%
1Y-26.8%-6.7%-20.8%

Return vs Industry: 6600 underperformed the Hong Kong Pharmaceuticals industry which returned -6.7% over the past year.

Return vs Market: 6600 underperformed the Hong Kong Market which returned -20.8% over the past year.

Price Volatility

Is 6600's price volatile compared to industry and market?
6600 volatility
6600 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement7.6%
Market Average Movement8.0%
10% most volatile stocks in HK Market14.8%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 6600 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6600's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990950Hong Zhaohttps://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome.

SciClone Pharmaceuticals (Holdings) Limited Fundamentals Summary

How do SciClone Pharmaceuticals (Holdings)'s earnings and revenue compare to its market cap?
6600 fundamental statistics
Market CapHK$4.12b
Earnings (TTM)HK$917.54m
Revenue (TTM)HK$2.93b

4.5x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6600 income statement (TTM)
RevenueCN¥2.66b
Cost of RevenueCN¥641.03m
Gross ProfitCN¥2.02b
Other ExpensesCN¥1.19b
EarningsCN¥832.86m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.23
Gross Margin75.92%
Net Profit Margin31.28%
Debt/Equity Ratio46.6%

How did 6600 perform over the long term?

See historical performance and comparison

Dividends

5.1%

Current Dividend Yield

23%

Payout Ratio